New Leukemia Treatment Boosts Remission Rates to 75%

Patients battling one of the most aggressive forms of blood cancer now have a powerful new weapon in their fight for survival.

Researchers at Dresden University Medicine have developed a breakthrough treatment for acute myeloid leukemia that's changing the game for patients who've run out of options. When standard chemotherapy fails or the cancer returns, doctors have struggled to help patients achieve remission before they can receive a potentially curative stem cell transplant.

The new approach combines traditional intensive chemotherapy with a drug called venetoclax. In the RELAX study, this combination pushed remission rates from a discouraging 40% to an impressive 75%. That means three out of four patients were able to get their leukemia under control enough to qualify for a stem cell transplant.

"If AML stops responding to conventional intensive chemotherapy or comes back, the chances of a long-term cure decrease significantly," explains Prof. Christoph Röllig, who led the study. The team needed to find a way to catch this fast-growing cancer before it was too late.

The treatment works by pairing standard drugs cytarabine and mitoxantrone with venetoclax, which targets a specific protein that helps cancer cells survive. The majority of patients treated with this combination successfully received their stem cell transplants, giving them a real shot at long-term survival.

Even more encouraging, the therapy shows promise against particularly stubborn genetic forms of the disease that have historically been hardest to treat. The researchers first tested the combination for safety, then confirmed its effectiveness across multiple medical centers throughout Germany.

The impact is already spreading beyond the initial study. More than 150 additional patients across Germany have received the treatment since the study ended, and early results continue to look promising.

The Ripple Effect

This breakthrough represents years of collaboration between academic researchers and industry partners, showing how different sectors working together can accelerate life-saving discoveries. The treatment is already being used in clinical practice while researchers gather more data, meaning patients don't have to wait years for access.

For families watching loved ones battle this aggressive cancer, the new therapy offers something precious: time and options. Getting patients to remission faster means they can move forward with transplants sooner, improving their chances of beating the disease for good.

The Dresden team continues analyzing results and refining the approach. Their work demonstrates how university hospitals can serve as innovation hubs, turning laboratory discoveries into real-world treatments that save lives.

Stem cell transplants remain the best path to a permanent cure for acute myeloid leukemia, but they only work if doctors can first get the cancer under control. This new combination therapy is proving to be the bridge patients desperately need.